KYMR - Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. , a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
As of May 13, 2026: spot at $85.46, ATM IV 57.9%, max pain $85.00, net GEX $54.6K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $7.04B
- Beta
- 2.06
- 52-Week Range
- 28.06-103
- CEO
- Nello Mainolfi
- Employees
- 208
- IPO Date
- Aug 21, 2020
- Exchange
- NASDAQ
What KYMR Looks Like to Options Traders Today
IV rank of 10.1% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($54.6K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.170) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The KYMR overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked KYMR overview questions
- What is KYMR?
- KYMR is the ticker symbol for Kymera Therapeutics, Inc., a listed security. Kymera Therapeutics, Inc. , a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. Listed on NASDAQ. KYMR is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the KYMR options snapshot look like today?
- As of May 13, 2026, the KYMR options snapshot shows spot at $85.46, ATM IV 57.9%, IV rank 10.1%, max pain $85.00, net GEX $54.6K, expected move 16.60%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are KYMR's key statistics?
- Kymera Therapeutics, Inc. (KYMR) carries a market capitalization of $7.04B, beta of 2.06 relative to the broader market, 52-week range of 28.06-103. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does KYMR belong to?
- Kymera Therapeutics, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare KYMR's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the KYMR data on this page?
- The options snapshot above is dated May 13, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).